ES2641089T3 - Terapia adyuvante mejorada de tumores que expresan G250 - Google Patents

Terapia adyuvante mejorada de tumores que expresan G250 Download PDF

Info

Publication number
ES2641089T3
ES2641089T3 ES12171081.8T ES12171081T ES2641089T3 ES 2641089 T3 ES2641089 T3 ES 2641089T3 ES 12171081 T ES12171081 T ES 12171081T ES 2641089 T3 ES2641089 T3 ES 2641089T3
Authority
ES
Spain
Prior art keywords
treatment
antigen
antibody
stage
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12171081.8T
Other languages
English (en)
Spanish (es)
Inventor
Olaf Wilhelm
Sven Warnaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Application granted granted Critical
Publication of ES2641089T3 publication Critical patent/ES2641089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES12171081.8T 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan G250 Expired - Lifetime ES2641089T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US584679P 2004-07-02

Publications (1)

Publication Number Publication Date
ES2641089T3 true ES2641089T3 (es) 2017-11-07

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12171081.8T Expired - Lifetime ES2641089T3 (es) 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan G250

Country Status (13)

Country Link
US (1) US7691375B2 (enExample)
EP (2) EP2497497B1 (enExample)
JP (1) JP2008505143A (enExample)
KR (1) KR101205289B1 (enExample)
CN (1) CN101052416B (enExample)
AU (1) AU2005259481B2 (enExample)
BR (1) BRPI0512854A (enExample)
CA (1) CA2566950A1 (enExample)
DK (1) DK2497497T3 (enExample)
ES (1) ES2641089T3 (enExample)
MX (1) MXPA06013240A (enExample)
RU (2) RU2371198C2 (enExample)
WO (1) WO2006002889A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
CA2492057A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
EP2479577A1 (en) 2009-09-18 2012-07-25 Mitsubishi Chemical Corporation Hepatocellular carcinoma marker
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105377295A (zh) 2013-02-22 2016-03-02 威丽克斯股份公司 基于caix分级的癌症治疗
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
WO2002063010A2 (en) 2001-02-07 2002-08-15 Wilex Ag Method of producing recombinant antibodies against tumors
ES2365606T3 (es) * 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
CA2492057A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Also Published As

Publication number Publication date
EP1763367A2 (en) 2007-03-21
WO2006002889A2 (en) 2006-01-12
JP2008505143A (ja) 2008-02-21
CN101052416A (zh) 2007-10-10
WO2006002889A3 (en) 2006-10-05
MXPA06013240A (es) 2007-02-28
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
CA2566950A1 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
AU2005259481A1 (en) 2006-01-12
US20070207157A1 (en) 2007-09-06
RU2371198C2 (ru) 2009-10-27
EP2497497A1 (en) 2012-09-12
KR20070036085A (ko) 2007-04-02
RU2519340C2 (ru) 2014-06-10
US7691375B2 (en) 2010-04-06
EP2497497B1 (en) 2017-06-21
RU2007104040A (ru) 2008-08-10
KR101205289B1 (ko) 2012-11-27
AU2005259481B2 (en) 2010-04-22
BRPI0512854A (pt) 2008-04-08

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
ES2938321T3 (es) Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1
ES2703572T3 (es) Tratamiento del cáncer basado en la estratificación de CAIX
Hitchcock et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma
Sun et al. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study
Hoekstra et al. Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion?
EP3752528A1 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
Lin et al. Immune microenvironment of primary and recurrent craniopharyngiomas: A study of the differences and clinical significance
Rizzieri et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Kawashima et al. Dose–volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma
Zhang et al. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
Zavos et al. Study of “de novo” malignancies among Greek renal transplant recipients
Freedman et al. Solitary late recurrence of renal cell carcinoma presenting as duodenal ulcer
RU2552289C1 (ru) Способ лечения местнораспространенного рака желудка с высокой метаболической и пролиферативной активностью
Macheiner et al. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy
Bird et al. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules
Kuroda et al. Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report
Marks et al. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater
Apfelbaum et al. LGG-02. ELUCIDATING THE ROLE OF FGFR1 ALTERATIONS IN PEDIATRIC GLIOMAS
Kuusk Lymphatic drainage in renal tumours and implications for management
Laguna Re: A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma
Karyağar et al. The Diagnostic Power of the Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Biochemical Recurrence After Primary Curative Treatment in Patients with Prostate Cancer: A Single-center Experience
Rajhans et al. Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors
KurKomelis Microvasculature of human tumor xenografts: a study of vascular hyperpermeability, fibrinogen influx and fibrin accumulation in two colon carcinomas
Iyad Sultan et al. Soft Tissue Sarcomas In Young Individuals